Efficacy and Safety Evaluation of Lumateperone in Acute Treatment of Manic Episodes in Bipolar I Disorder: A Randomized, Double-Blind, Placebo-Controlled Study

The primary objective of this study is to evaluate the **efficacy** of lumateperone 42 mg, administered once daily, compared to placebo in the acute treatment of patients experiencing manic episodes or manic episodes with mixed features associated with **Bipolar I Disorder**. This is measured by the change from baseline to the end of Week 3 in the Young Mania Rating Scale (YMRS) total score. The clinical relevance of this objective lies in its potential to provide a new therapeutic option for managing acute manic episodes in patients with Bipolar I Disorder, thereby improving patient outcomes and quality of life.

Secondary objectives include assessing the efficacy of lumateperone 42 mg compared to placebo in the same patient population, as measured by the change from baseline to the end of Week 3 in the Clinical Global Impression-Severity (CGI-S) score. This secondary measure provides additional insights into the overall clinical impression of the severity of the disorder, complementing the primary efficacy assessment.

The clinical trial involves a total of **318 participants** diagnosed with **Bipolar I Disorder (Bipolar Mania)**. The study population includes both male and female inpatients aged between 18 and 75 years. Participants were selected based on their diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision criteria, specifically those experiencing a current episode of mania or mania with mixed features, with or without psychotic symptoms. The trial population is characterized by individuals who have been hospitalized voluntarily or admitted to an inpatient unit due to a manic episode. The study does not specify particular lifestyle considerations such as diet or physical activity. The selection criteria ensure that participants have a moderate severity of illness, as indicated by specific scores on the Young Mania Rating Scale and the Clinical Global Impressions Scale. The trial includes a vulnerable population, reflecting the acute nature of the condition being studied.

The clinical trial is designed as a **randomized, double-blind, placebo-controlled** study to evaluate the efficacy and safety of **lumateperone** in the acute treatment of patients experiencing manic episodes or manic episodes with mixed features associated with **Bipolar I Disorder**. The trial will involve the administration of lumateperone 42 mg once daily, compared to a placebo, over a period of three weeks. The primary efficacy endpoint is the change from baseline to the end of Week 3 in the Young Mania Rating Scale (YMRS) total score, while a secondary endpoint includes the change in the Clinical Global Impressions-Severity (CGI-S) score over the same period.

Participants will be involved in the study for a total duration of three weeks, with the trial estimated to conclude by July 2026. The study will commence with a screening visit to confirm eligibility, which includes criteria such as a diagnosis of Bipolar I Disorder with a current manic episode, a YMRS total score of at least 20, and a CGI-S score of at least 4. Following the screening, eligible participants will be randomized to receive either lumateperone or placebo. Study visits will occur weekly to monitor efficacy and safety, with assessments conducted at baseline and at the end of each week. The end-of-study visit will coincide with the completion of the three-week treatment period, where final assessments will be made.

Participants are expected to remain in the study for the full three-week duration unless conditions arise that necessitate early termination, such as adverse events or withdrawal of consent. The trial is not categorized as low intervention and is classified as a Phase 3 trial, indicating it involves a drug not currently authorized for the population under study. The trial will adhere to rigorous standards to ensure the integrity and reliability of the data collected, with all procedures conducted in accordance with ethical guidelines and regulatory requirements.

The clinical trial involves the administration of **lumateperone**, an experimental medication, in the form of capsules. Each capsule contains 42 mg of lumateperone, which is a chemical compound. The medication is administered orally once daily. The maximum treatment period for lumateperone is three weeks, with a total maximum dose of 0.88 grams. The primary objective of the study is to evaluate the efficacy of lumateperone in the acute treatment of patients experiencing manic episodes or manic episodes with mixed features associated with Bipolar I Disorder. Participant compliance with the dosing schedule is monitored throughout the study to ensure adherence to the treatment protocol.

The study also includes a **placebo** group, where participants receive placebo capsules that are identical in appearance to the lumateperone capsules. These placebo capsules contain the same excipient ingredients as the lumateperone capsules but do not include the active compound. The placebo is administered orally once daily, following the same dosing schedule as the lumateperone group. The use of placebo allows for a double-blind, placebo-controlled study design, which is essential for assessing the true efficacy and safety of the experimental medication. Compliance with the placebo administration is similarly monitored to maintain the integrity of the study results.

The efficacy of lumateperone in the treatment of **bipolar I disorder** with manic episodes or manic episodes with mixed features will be assessed in this clinical trial. The primary efficacy endpoint is the change from baseline to the end of Week 3 in the Young Mania Rating Scale (YMRS) total score. This scale is a widely used, validated tool for measuring the severity of manic episodes. The secondary efficacy endpoint is the change from baseline to the end of Week 3 in the Clinical Global Impressions-Severity (CGI-S) score, which provides an overall clinician-determined summary measure of the patient's current state.

Participants will receive lumateperone 42 mg or placebo once daily, and efficacy assessments will be conducted at baseline and at the end of Week 3. The YMRS and CGI-S scores will be collected and analyzed to determine the efficacy of the treatment. The trial is designed as a multicenter, randomized, double-blind, placebo-controlled study, ensuring that the results are robust and reliable. The study aims to provide comprehensive data on the efficacy of lumateperone in the acute treatment of patients with bipolar I disorder.